您的当前位置:首页 > 行业数据 > 全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发
图片属性
图片格式:PNG 图片大小:355KB 图片尺寸:2317*958
同报告图片
 / 4
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发_第1页
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
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发_第2页
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
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发_第3页
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发_第4页
fCDpobnnm64gICAgICAgICAgICAgICAgfCDkuK3lm70gICAgICAgICAgfCDnvo7lm70gICAgICAgICAgfCDkuK3nvo7lkIjorqEgICAgICAgIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tfAp8IOW5tOWPkeeXheeOhyAgICAgICAgICAgIHwgfjYwLDAwMCAgICAgICB8IH4xNCwwMDAgICAgICAgfCDigJQgICAgICAgICAgICAgICB8Cnwg5ZWG5Lia5r2c5Yqb77yIVVMk77yJICAgICB8IH5VUyQ2NTBtICAgICAgfCB+VVMkODUwbSAgICAgIHwgflVTJDEuNWJuICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOi1hOaWmQ==
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发_第5页
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
所属报告: 和誉(2256.HK)-港股公司首次覆盖:中国小分子新药研发标兵迎接商业化转型元年-251002(44页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠